LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

44.21 3.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.32

Max

44.42

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.57% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 3.2B
Eelmine avamishind	40.94
Eelmine sulgemishind	44.21

Uudiste sentiment

By Acuity

50%

149 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. veebr 2026, 22:36 UTC

Tulu

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. veebr 2026, 22:32 UTC

Tulu

Woodside Energy Fiscal Year Net Profit Falls 24%

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

23. veebr 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. veebr 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Crescent Capital Partners Owns 53% of ClearView Wealth

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. veebr 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. veebr 2026, 23:27 UTC

Tulu

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. veebr 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. veebr 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. veebr 2026, 22:31 UTC

Tulu

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. veebr 2026, 22:24 UTC

Tulu

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Underlying Ebitda A$700.9 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. veebr 2026, 22:20 UTC

Tulu

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

31.57% tõus

12 kuu keskmine prognoos

Keskmine 55.56 USD 31.57%

Kõrge 66 USD

Madal 44 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

149 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.